FDA Adverse Event Injury Summary report: N

GORE VIABAHN ENDOPROSTHESIS

MDR report key: 10354711 · Received August 3, 2020

Report

Report Number
2017233-2020-01071
Event Type
Injury
Date Received
August 3, 2020
Date of Event
February 22, 2019
Report Date
August 3, 2020
Manufacturer
W. L. GORE & ASSOCIATES, INC.
Product Code
PFV
PMA / PMN Number
P040037
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

A REVIEW OF THE MANUFACTURING RECORDS COULD NOT BE PERFORMED AS DEVICE ITEM/LOT NUMBERS WERE NOT AVAILABLE. THE IMAGES AND DEVICE WERE NOT AVAILABLE, THE IMAGING EVALUATION AND ENGINEERING EVALUATION COULD NOT BE PERFORMED.

Description of Event or Problem · 1

THE FOLLOWING PUBLICATION WAS REVIEWED: " ENDOVASCULAR AORTIC REPAIR IS A VIABLE STRATEGY FOR TREATMENT OF PRIMARY INFECTED ABDOMINAL AORTIC ANEURYSM¿ RECEIVED THROUGH ANN VASC SURG 2020; 63: 117¿128. THE AUTHORS: XIAO DI, CHANGWEI LIU, RONG ZENG, AND LENG NI. THE ARTICLE AIMED THAT INFECTED ABDOMINAL AORTIC ANEURYSM (IAAA) IS RARE, AND INFORMATION IS LIMITED WHETHER ENDOVASCULAR AORTIC REPAIR (EVAR) CAN BE CONSIDERED A PERMANENT TREATMENT OR IS A TEMPORARY FIX PRECEDING OPEN SURGERY. THIS RETROSPECTIVE STUDY REVIEWED THE SHORT- AND LONGTERM OUTCOMES OF OPEN SURGERY, EMERGENT EVAR, AND ELECTIVE EVAR IN THE TREATMENT OF PRIMARY IAAA. THE STUDY POPULATION COMPRISED 19 PATIENTS TREATED FOR IAAA AT PEKING UNION MEDICAL COLLEGE HOSPITAL BETWEEN JANUARY 2008 AND JANUARY 2017. THE PATIENT (PATIENT 5) HAD LEFT IA STENOSIS, LEFT FA OCCLUSION(IMPLANTED WITH FENESTRATED GORE 23-12-120, LEFT FA VIABAHN 11-100; RIGHT FA VIABAHN 10-100) AND UNDERWENT AN ILIAC ARTERY STENT PLACEMENT WITH FEMORAL ARTERY ENDARTERECTOMY, 2 WEEKS AFTER THE FIRST PROCEDURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
819863 GORE VIABAHN ENDOPROSTHESIS ENDOVASCULAR GRAFT, ARTERIOVENOUS DIALYSIS ACCESS CIRCUIT STENOSIS TREATMENT PFV W. L. GORE & ASSOCIATES, INC.

Patients

Seq Age Sex Outcome Treatment
1 43 YR Required Intervention